1. Scrip
  2. >>Focus On Asia

Emerging Modalities Stand Out In Recovering Korean Deal Market

ADCs, TPDs Gain Prominence

 
• By Jung Won Shin

While Korean biopharma companies’ out-licensing deals have remained lackluster in the past couple of years, activity around emerging modalities, led by ADCs, have been increasing in line with global trends.

dealmaking
LigaChem, Orum Lead ADC Deals, While SK Biopharm Moves Into TPD, RPT • Source: Shutterstock

As South Korea aims to foster the development of global blockbuster drugs and top-tier internationalized biopharma firms in the coming years, amid limited financial and labor resources as well as other road blocks, it is crucial for companies to adopt more efficient and effective strategies along with the government’s strong support.

A new policy report from the Korea Pharmaceutical and Bio-Pharma Manufacturers’ Association (KPBMA) notes that licensing activities and mergers and...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from South Korea

More from Focus On Asia

Torrent Acquires JB Chem In 2025’s Biggest Deal For Indian Pharma

 
• By Vibha Ravi

Torrent Pharma’s JB Chemicals acquisition follows the Curatio deal and Boehringer brands buyout. The second-biggest deal ever and the largest in 2025 among domestic pharma companies helps Torrent fill white spaces in areas like nephrology and gives an entry into the CDMO segment

Snapshot Of India’s Pharma Manufacturing Network Amid ‘Trumponomics’

 
• By Anju Ghangurde

Scrip collates data on the global manufacturing network of leading Indian drug makers, the markets serviced and production hubs for active pharmaceutical ingredients. Will ongoing geopolitical tensions and policy shifts have a bearing on some of these down the line?

GSK, Bharat On Shigella Vaccine Phase II Data Timelines, Malaria Vaccine Price Halving

 
• By Vibha Ravi

GSK tells Scrip about timelines for data expected from two Phase II trials for its Bharat Biotech-partnered shigella vaccine candidate, which puts it ahead of Limmatech/Valneva. Meanwhile, a global-first malaria vaccine, also partnered with Bharat, sees an over 50% price cut